BPC-157 and TB-500 dosing schedule

This article is for educational purposes only. Nothing here is medical advice. BPC-157 and TB-500 are not approved medicines in the EU, UK, or US, and both are prohibited by WADA. PeptideMethods does not recommend, endorse, or facilitate the purchase of either peptide.

The honest answer: no validated schedule exists

Neither BPC-157 nor TB-500 has a validated dosing regimen for humans. A 2026 review of injectable peptide therapy for sports medicine physicians stated plainly that for both compounds, ^[1]. There are no published Phase 2 or Phase 3 clinical trials for either peptide in any indication, and the pharmaceutical science needed to anchor a safe human dose has not been completed^[2]. This is the starting point for any honest discussion of their administration schedules.

What the preclinical literature actually used

Most published BPC-157 animal studies administer the peptide intraperitoneally at doses of 10 micrograms per kilogram or 10 nanograms per kilogram of body weight, typically once daily for the duration of the experiment^[3]. These doses are not equivalent to the subcutaneous injections described in online discussions; the conversion from rodent intraperitoneal dosing to human subcutaneous dosing requires pharmacokinetic data that BPC-157 does not have. A 2026 pharmaceutical science paper confirmed that BPC-157 has a plasma half-life under 30 minutes yet produces biological effects lasting hours to days, a mismatch that makes standard dose extrapolation unreliable^[2]. There is no pharmaceutical-grade formulation and no validated dosing regimen on record.

TB-500, the grey-market label used for either the synthetic heptapeptide AC-LKKTETQ or full-length thymosin beta-4, has a different evidentiary situation. The only Western-standard human trial using a related formulation is a small Phase 3 study in neurotrophic keratopathy (an ophthalmic condition), which used a 0.1% topical eye-drop solution called RGN-259 at multiple daily applications to the eye surface^[4]. That topical route and dose have no bearing on the subcutaneous injection schedules commonly discussed online. A 2024 pharmacokinetic study in rats found that the primary TB-500 metabolite peaked within 0 to 6 hours and a secondary metabolite persisted up to 72 hours, which suggests the peptide clears relatively quickly but leaves activity markers well beyond the initial dose window^[5].

Why online dosing figures are not data

The ranges frequently cited in forums (200 to 500 micrograms of BPC-157 once or twice daily; 2 to 5 milligrams of TB-500 weekly or biweekly) are not drawn from controlled clinical trials. They are extrapolations from rodent study doses, adjusted by body weight using scaling factors that assume similar pharmacokinetics between species. That assumption has not been validated for either peptide in controlled human studies.

The FDA's position on BPC-157 is that there is no legal basis for compounding pharmacies to prepare it for human use, and that no one knows whether there is a safe dose or any safe method of administration^[6]. The FDA and the US Anti-Doping Agency both note that BPC-157 carries safety risks that cannot currently be characterised because human data are essentially absent^[6].

Frequency: continuous versus pulsed

Animal studies have generally used daily or near-daily administration for defined repair intervals, typically two to four weeks in injury models^[3]. Some forum discussion speculates that the pharmacokinetics of TB-500 might support less frequent dosing given the 72-hour metabolite persistence seen in rats^[5], but this is not confirmed in human pharmacokinetic studies because those studies do not exist. Whether continuous dosing, loading-then-maintenance schedules, or periodic pulsing produces better or safer outcomes in humans is an open question.

A 2026 review in Sports Medicine noted the broader concern: unapproved peptides marketed for musculoskeletal recovery carry potential for serious harm precisely because the human safety profile is uncharacterised. Frequency and dose interact with safety signals in ways that can only be mapped in controlled trials.

Regulatory position and what it means for sourcing

Both peptides are sold as research chemicals online. In the US, BPC-157 is an unapproved new drug; the FDA's Pharmacy Compounding Advisory Committee reviewed both peptides at its July 2026 meeting specifically to assess whether any compounding pathway is permissible. The preliminary position was that BPC-157 should not be on the 503A compounding list because safety data are insufficient^[6]. For TB-500, thymosin beta-4 is in Category 2 of the FDA 503A bulks list, which effectively bars compounding pharmacies from preparing it. The WADA 2026 prohibited list classifies BPC-157 under S0 (unapproved substances) and TB-500 under S2 (peptide hormones, growth factors, and related substances), meaning both are prohibited in and out of competition for any athlete subject to anti-doping rules.

What to do with this information

If you are trying to decide whether to use these peptides for injury recovery, the relevant facts are: there is no validated human dose, there is no validated schedule, and neither compound is approved for human use in any country we cover. The preclinical literature on tissue repair is active and in some cases interesting, but it does not support clinical recommendations. The conversation about whether any of this is appropriate for your situation belongs with a clinician who can review your individual circumstances, medical history, and the jurisdiction-specific legal position. Country-specific regulatory detail is on the BPC-157 peptide page and the TB-500 peptide page.